Sandoz Group AG (XSWX:SDZ) Total Stockholders Equity: CHF7,478 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SDZ Sandoz Group AG XSWX:SDZ
11 GF Score
Price CHF63.52
! 3 Warning Signs
View Full Analysis

What is Sandoz Group AG Total Stockholders Equity?

Sandoz Group AG XSWX:SDZ -0.16% 11 Total Stockholders Equity is CHF7,478 Mil as of Dec. 2025. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Sandoz Group AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF7,478 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sandoz Group AG's Book Value per Share for the quarter that ended in Dec. 2025 was CHF17.28. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sandoz Group AG's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.61.


Sandoz Group AG  (XSWX:SDZ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sandoz Group AG's Book Value per Share for the quarter that ended in Dec. 2025 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sandoz Group AG's Debt-to-Equity for the quarter that ended in Dec. 2025 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sandoz Group AG Total Stockholders Equity Related Terms


Sandoz Group AG Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Total Stockholders Equity Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
8,149.64 7,476.20 7,278.13 7,478.11

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial 7,476.20 7,478.43 7,278.13 7,172.42 7,478.11
XSWX:SDZ
11GF Score
Sandoz Group AG XSWX:SDZ
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of CHF7,478 Mil mean?
Sandoz Group AG (XSWX:SDZ) has a Total Stockholders Equity of CHF7,478 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sandoz Group AG and its competitors.
Is Sandoz Group AG's Total Stockholders Equity too high?
Sandoz Group AG's current Total Stockholders Equity is CHF7,478 Mil. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Total Stockholders Equity compare to ZTS and UTHR?
Sandoz Group AG's Total Stockholders Equity of CHF7,478 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sandoz Group AG and its competitors. Sandoz Group AG's current Total Stockholders Equity is CHF7,478 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Total Stockholders Equity of CHF7,478 Mil. The current Total Stockholders Equity is CHF7,478 Mil. Sandoz Group AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Total Stockholders Equity is CHF7,478 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score

Get the complete analysis for XSWX:SDZ

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF63.52
Price